Pardeep Nijhawan

This profile gathers the share dealings of Pardeep Nijhawan in Edesa Biotech, Inc., where the filings describe the role as chief executive. In total, 80 filings cover trades dated from 7 June 2019 to 5 October 2026.

On the market, this insider has only ever bought: 31 purchases, €377k in total. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 48 share grants. 2026 to date brings 8 purchases and no sales.

In size, the median ticket on the buying side is €5,680. 14 out of 31 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. Ninety days after publication, 18 purchases show a median change of -29.5%, with the price up in 33% of them. Past outcomes like these are no guarantee of what comes next.

The newest entry dates from 6 October 2026: a share grant, in Edesa Biotech, Inc. The last insider purchase was made public on 10 March 2026, 228 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.